Virologic Failure with Abacavir — ACTG 5202 and the GSK Response

This year’s International AIDS Conference delivered conflicting information about the virologic efficacy of abacavir/3TC.

ACTG 5202 is an important ongoing study of initial treatment strategies for HIV infection; it includes a blinded comparison of fixed-dose tenofovir/FTC versus abacavir/3TC, each together with efavirenz or boosted atazanavir. At this year’s International AIDS Conference, Paul Sax presented results of the NRTI comparison among 797 study participants who had baseline viral loads ≥100,000 copies/mL; median follow-up was 60 weeks [Abstract THAB0303]. Although these results were described in a press release earlier this year (AIDS Clin Care Mar 10 2008), this is the first time they have been presented in detail.

Among persons with viral loads ≥100,000 copies/mL at screening, time to virologic failure was significantly shorter among those randomize…

Author

Charles B. Hicks, MD

Disclosures

Consultant / Advisory boardGilead Sciences; ViiV; Merck

RoyaltiesUpToDate, Inc.

Grant / Research supportNIH; Department of Health and Human Services

Charles B. Hicks, MD

Disclosures

Consultant / Advisory boardGilead Sciences; ViiV; Merck

RoyaltiesUpToDate, Inc.

Grant / Research supportNIH; Department of Health and Human Services

Virologic Failure with Abacavir — ACTG 5202 and the GSK Response

Topics

Author